CNS PharmaceuticalsCNSP
13F holders, Q1 2025 (March 31)7holders
$1.36avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding CNS Pharmaceuticals Inc. (CNSP) in their 13F filings. The largest holders were UBS Group AG ($33K), Ground Swell Capital, LLC ($15K) and Tower Research Capital LLC (TRC) ($7K).
- Company
- CNS Pharmaceuticals Inc.
- CUSIP
- 18978H409
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $55K |
| Exits | 0 | $0 |
Ownership 7 holders
| UBS Group AG | 0.00% | New | 23,978 | $33K |
| Ground Swell Capital, LLC | 0.04% | New | 11,341 | $15K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 5,111 | $7K |
| Barrett & Company, Inc. | 0.00% | New | 100 | $136 |
| MAI Capital Management | 0.00% | New | 40 | $55 |
| SBI Securities Co., Ltd. | 0.00% | New | 15 | $20 |
| Bank of America Corp. | 0.00% | New | 9 | $12 |
"% of holder's portfolio" is CNSP's weight in each manager's 13F, not the share of CNS Pharmaceuticals Inc. the manager owns.